View source for Non small cell lung cancer future or investigational therapies

__NOTOC__
{{Non small cell lung cancer}}
{{CMG}}; {{AE}}  {{MV}}

==Overview==
The '''KEYNOTE-024 trial''' used pembrolizumab (a monoclonal antibody against programmed death 1) in patients with advanced non-small cell lung cancer and PD-L1 expression. Pembrolizumab was associated with significantly longer progression-free and overall survival. The reported adverse events were lower than those of platinum-based chemotherapy. <ref name="NEJM">Martin Reck, M.D. et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine. October 9 2016  DOI: 10.1056/NEJMoa1606774 http://www.nejm.org/doi/full/10.1056/NEJMoa1606774</ref> 

==Future or Investigational Therapies==
===KEYNOTE-024 trial===
*Phase III, open-label, randomized clinical trial<ref name="pmid26712084">{{cite journal| author=Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY et al.| title=Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. | journal=Lancet | year= 2016 | volume= 387 | issue= 10027 | pages= 1540-50 | pmid=26712084 | doi=10.1016/S0140-6736(15)01281-7 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26712084  }} </ref> 
*Patients with untreated, advanced non-small cell lung cancer and PD-L1 expression<ref name="pmid26712084">{{cite journal| author=Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY et al.| title=Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. | journal=Lancet | year= 2016 | volume= 387 | issue= 10027 | pages= 1540-50 | pmid=26712084 | doi=10.1016/S0140-6736(15)01281-7 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26712084  }} </ref>
*Pembrolizumab was associated with:<ref name="pmid26712084">{{cite journal| author=Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY et al.| title=Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. | journal=Lancet | year= 2016 | volume= 387 | issue= 10027 | pages= 1540-50 | pmid=26712084 | doi=10.1016/S0140-6736(15)01281-7 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26712084  }} </ref>
:*Significantly longer progression-free (10.3 months) and overall survival at 6 months (80.2%) 
:*Low adverse events compared to platinum-based chemotherapy

==References==
{{reflist|2}}

[[Category:Hematology]]
[[Category:Types of cancer]]
[[Category:Disease]]

{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
 [[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Pulmonology]]
[[Category:Surgery]]